help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nam, T. J.
Right arrow Articles by Clemmons, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nam, T. J.
Right arrow Articles by Clemmons, D. R.
Endocrinology Vol. 138, No. 7 2972-2983
Copyright © 1997 by The Endocrine Society

ARTICLES

Insulin-Like Growth Factor Binding Protein-5 Binds to Plasminogen Activator Inhibitor-I2

Taek Jeong Nam, Walker Busby, Jr. and David R. Clemmons

Taek Jeong Nam, Walker Busby, Jr. and David R. Clemmons

Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599

Address all correspondence and requests for reprints to: David R. Clemmons, M.D., Division of Endocrinology, Department of Medicine CB 7170, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7170.

Insulin-like growth factor binding protein-5 (IGFBP-5) has been shown to bind to the extracellular matrix (ECM) of both fibroblasts and smooth muscle cells. The ECM-IGFBP-5 interaction is mediated in part by binding to heparan sulfate containing proteoglycans. Because proteoglycans may not be the only components of ECM that bind to IGFBP-5, we have determined its ability to bind to other ECM proteins. When a partially purified mixture of the proteins that were present in fibroblast conditioned medium was purified by IGFBP-5 affinity chromatography, a 55-kDa protein was eluted. Amino acid sequencing of the amino terminal 28 amino acids showed that it was human plasminogen activator inhibitor-1 (PAI-1). To determine if this interaction was specific, purified human PAI-1 was incubated with IGFBP-5 and the IGFBP-5/PAI-1 complex immunoprecipitated with anti-PAI-1 antiserum. When the precipitate was analyzed by immunoblotting using anti-IGFBP-5 antiserum, the intensity of the IGFBP-5 band was substantially increased compared with controls that did not contain human PAI-1. A synthetic IGFBP-5 peptide that contained the amino acid sequence between positions 201 and 218 inhibited IGFBP-5/PAI-1 interaction. Coincubation of IGFBP-5 mutants that contained substitutions for specific basic residues located between positions 201 and 218 with PAI-1 indicated that some of these amino acids were important for binding. Two mutants that contained neutral substitutions for specific basic amino acids within the glycosaminoglycan binding domain had reduced binding to PAI-1. In contrast, three other mutants that also had substitutions for charged residues in the same region had no reduction in binding. Heparin and heparan sulfate inhibited the IGFBP-5/PAI-1 interaction; however, several other glycosaminoglycans had no effect. PAI-1 was determined to be an important ECM component for binding because approximately 27% of total ECM binding could be inhibited with anti-PAI-1 antiserum. Competitive binding studies with unlabeled IGFBP-5 showed that the dissociation constant of PAI-1 for IGFBP-5 was 9.1 x 10-8 M. In summary, IGFBP-5 binds specifically to plasminogen activator inhibitor-1. Because this is present in the extracellular matrix of several cell types, it may be one of the important binding components of ECM. PAI-1 binding partially protects IGFBP-5 from proteolysis, suggesting that it is one of the ECM components that is involved in mediating this effect.




This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
S. M. Hauck, C. J. Gloeckner, M. E. Harley, S. Schoeffmann, K. Boldt, P. A. R. Ekstrom, and M. Ueffing
Identification of Paracrine Neuroprotective Candidate Proteins by a Functional Assay-driven Proteomics Approach
Mol. Cell. Proteomics, July 1, 2008; 7(7): 1349 - 1361.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. E. DeMambro, D. R. Clemmons, L. G. Horton, M. L. Bouxsein, T. L. Wood, W. G. Beamer, E. Canalis, and C. J. Rosen
Gender-Specific Changes in Bone Turnover and Skeletal Architecture in Igfbp-2-Null Mice
Endocrinology, May 1, 2008; 149(5): 2051 - 2061.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Mukherjee, E. M. Wilson, and P. Rotwein
Insulin-Like Growth Factor (IGF) Binding Protein-5 Blocks Skeletal Muscle Differentiation by Inhibiting IGF Actions
Mol. Endocrinol., January 1, 2008; 22(1): 206 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
K. S. Kim, Y. B. Seu, S.-H. Baek, M. J. Kim, K. J. Kim, J. H. Kim, and J.-R. Kim
Induction of Cellular Senescence by Insulin-like Growth Factor Binding Protein-5 through a p53-dependent Mechanism
Mol. Biol. Cell, November 1, 2007; 18(11): 4543 - 4552.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Ning, B. Hoang, A. G. P. Schuller, T. P. Cominski, M.-S. Hsu, T. L. Wood, and J. E. Pintar
Delayed Mammary Gland Involution in Mice with Mutation of the Insulin-Like Growth Factor Binding Protein 5 Gene
Endocrinology, May 1, 2007; 148(5): 2138 - 2147.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M.-C. Alessi and I. Juhan-Vague
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
D J Flint, M Boutinaud, C B A Whitelaw, G J Allan, and A F Kolb
Prolactin inhibits cell loss and decreases matrix metalloproteinase expression in the involuting mouse mammary gland but fails to prevent cell loss in the mammary glands of mice expressing IGFBP-5 as a mammary transgene.
J. Mol. Endocrinol., June 1, 2006; 36(3): 435 - 448.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. M. Sorrell, J. H. Shand, E. Tonner, M. Gamberoni, P. A. Accorsi, J. Beattie, G. J. Allan, and D. J. Flint
Insulin-like Growth Factor-binding Protein-5 Activates Plasminogen by Interaction with Tissue Plasminogen Activator, Independently of Its Ability to Bind to Plasminogen Activator Inhibitor-1, Insulin-like Growth Factor-I, or Heparin
J. Biol. Chem., April 21, 2006; 281(16): 10883 - 10889.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. J. Allan, E. Tonner, M. Szymanowska, J. H. Shand, S. M. Kelly, K. Phillips, R. A. Clegg, I. F. Gow, J. Beattie, and D. J. Flint
Cumulative Mutagenesis of the Basic Residues in the 201-218 Region of Insulin-Like Growth Factor (IGF)-Binding Protein-5 Results in Progressive Loss of Both IGF-I Binding and Inhibition of IGF-I Biological Action
Endocrinology, January 1, 2006; 147(1): 338 - 349.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. C. Russo, B. S. Schutt, E. Andaloro, S. I. Ymer, A. Hoeflich, M. B. Ranke, L. A. Bach, and G. A. Werther
Insulin-Like Growth Factor Binding Protein-2 Binding to Extracellular Matrix Plays a Critical Role in Neuroblastoma Cell Proliferation, Migration, and Invasion
Endocrinology, October 1, 2005; 146(10): 4445 - 4455.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Oesterreicher, W. F. Blum, B. Schmidt, T. Braulke, and B. Kubler
Interaction of Insulin-like Growth Factor II (IGF-II) with Multiple Plasma Proteins: HIGH AFFINITY BINDING OF PLASMINOGEN TO IGF-II AND IGF-BINDING PROTEIN-3
J. Biol. Chem., March 18, 2005; 280(11): 9994 - 10000.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. Beattie, K. Phillips, J. H Shand, M. Szymanowska, D. J Flint, and G. J Allan
Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis
J. Mol. Endocrinol., February 1, 2005; 34(1): 163 - 175.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Noble, C. Towne, L. Chopin, D. Leavesley, and Z. Upton
Insulin-Like Growth Factor-II Bound to Vitronectin Enhances MCF-7 Breast Cancer Cell Migration
Endocrinology, June 1, 2003; 144(6): 2417 - 2424.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. M. Firth and R. C. Baxter
Cellular Actions of the Insulin-Like Growth Factor Binding Proteins
Endocr. Rev., December 1, 2002; 23(6): 824 - 854.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
C. McCaig, C. M. Perks, and J. M. P. Holly
Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin
J. Cell Sci., November 15, 2002; 115(22): 4293 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Nam, A. Moralez, and D. Clemmons
Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions
Endocrinology, January 1, 2002; 143(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. R. Clemmons
Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships
Endocr. Rev., December 1, 2001; 22(6): 800 - 817.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. A. BLOOR, R. A. KNIGHT, R. K. KEDIA, M. A. SPITERI, and J. T. ALLEN
Differential mRNA Expression of Insulin-like Growth Factor-1 Splice Variants in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis
Am. J. Respir. Crit. Care Med., July 15, 2001; 164(2): 265 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. C. Baxter
Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities
Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T.-J. Nam, W. H. Busby Jr., C. Rees, and D. R. Clemmons
Thrombospondin and Osteopontin Bind to Insulin-Like Growth Factor (IGF)-Binding Protein-5 Leading to an Alteration in IGF-I-Stimulated Cell Growth
Endocrinology, March 1, 2000; 141(3): 1100 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. W. Gregory, D. Kim, P. Ye, A. J. D’Ercole, T. G. Pretlow, J. L. Mohler, and F. S. French
Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft
Endocrinology, May 1, 1999; 140(5): 2372 - 2381.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. M. Twigg, M. C. Kiefer, J. Zapf, and R. C. Baxter
Insulin-like Growth Factor-binding Protein 5 Complexes with the Acid-labile Subunit. ROLE OF THE CARBOXYL-TERMINAL DOMAIN
J. Biol. Chem., October 30, 1998; 273(44): 28791 - 28798.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
A. Parker, C. Rees, J. Clarke, W. H. Busby Jr., and D. R. Clemmons
Binding of Insulin-like Growth Factor (IGF)-Binding Protein-5 to Smooth-Muscle Cell Extracellular Matrix Is a Major Determinant of the Cellular Response to IGF-I
Mol. Biol. Cell, September 1, 1998; 9(9): 2383 - 2392.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
B. Zheng, J. B. Clarke, W. H. Busby, C. Duan, and D. R. Clemmons
Insulin-Like Growth Factor-Binding Protein-5 Is Cleaved by Physiological Concentrations of Thrombin
Endocrinology, April 1, 1998; 139(4): 1708 - 1714.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society